Real-world (RW) second-line (2L) treatment (tx) patterns and clinical outcomes in patients (pts) with HER2-overexpressing biliary tract cancer (BTC).

Real-world second-line treatment patterns and clinical outcomes after first-line therapy failure — specific disease area pending full publication confirmation. Note: flagged for manual verification of disease area and partner institutions.

Target RWE researchers analyzed real-world data to characterize second-line treatment patterns, switching rates, and clinical outcomes among patients who failed first-line therapy, providing evidence on treatment sequencing in routine clinical practice.

Characterizing second-line treatment patterns and outcomes provides pharma partners developing second-line therapies with competitive context and patient profiling data for positioning new agents.

Second-line treatment pattern and outcome characterization for pharma partner competitive and gap analysis, Clinical outcomes after first-line failure evidence supporting label and commercial strategy for second-line agents